LifeTech Scientific Corporation Announces 2025 Interim Results: Core Business Demonstrated Resilience, Domestic and Overseas Sales Both Increased
HONG KONG, Aug. 29, 2025 /PRNewswire/ -- LifeTech Scientific Corporation ("LifeTech" or the "Company", together with its subsidiaries, the "Group", stock code: 1302.HK), a medical device company specializing in minimally invasive interventional solutions for cardio-cerebrovascular and peripheral vascular diseases, today announced its unaudited consolidated results for the six months ended 30 June 2025 (the "Reporting Period").
Revenue Growth: The Group achieved revenue of approximately RMB676.7 million during the Reporting Period, representing a year-on-year increase of approximately 3.7%.
Stable Profitability: Gross profit was approximately RMB497.8 million. Excluding certain non-recurring items[1], net profit attributable to owners of the Company was approximately RMB238.5 million, representing a year-on-year increase of approximately 2.1%.
Strong Cash Position: As at 30 June 2025, the Group's cash and cash equivalents amounted to approximately RMB782.6 million, representing an increase of approximately 17.5% compared with 31 December 2024.
Note [1]: Such non-recurring items include (i) the other gains arising from financial assets at fair value through profit or loss ("FVTPL"); and (ii) the share-based payment expenses.
Increase in Both Domestic and Overseas Sales
In the first half of 2025, the Group continued to implement a proactive and prudent development strategy, with a strong focus on addressing unmet clinical needs worldwide. By leveraging its synergies in branding, intellectual property, distribution, clinical registration, and global operations, the Group strengthened its long-term growth fundamentals and achieved sales growth in both domestic and overseas markets, driven by an expanding portfolio of innovative products and professional academic services.
China's mainland remained the foundation and largest market of the Group, where the sales generated accounted for approximately 74.1% of the total revenue of the Group during the Reporting Period. The Group continued to deepen its presence in the mainland China market, achieving a sales increase of approximately 2.2% year-on-year in the first half of 2025.
Meanwhile, overseas business maintained its upward momentum. Benefiting from proactive expansion and effective marketing strategies, the Group's overseas sales grew by approximately 8.0% year-on-year. Asia (excluding China's mainland) and Europe were the two largest overseas markets of the Group, where the sales generated accounted for approximately 11.4% and 11.0%, respectively, of the total revenue.
Core Business Demonstrated Resilience
The Group currently has three main product lines, covering the Structural Heart Diseases (SHD) business, the Peripheral Vascular Diseases (PVD) business and the Cardiac Pacing and Electrophysiology (CPE) business.
The revenue of the Group was approximately ...
